Autoimmune diseases are characterized by the production of autoantibodies specific for selfantigens by activated B cells. However, the precise mechanism for the pathogenesis of autoimmunity remains unknown. Intravenous immunoglobulin (IVIg), which is manufactured from the pooled plasma of more than tens of thousands of healthy volunteers, is used successfully for the treatment of inflammatory and autoimmune disease, especially in case of resistance to conventional therapy such as steroid pulse therapy. 
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